Events & Presentations

2017 European Society for Medical Oncology (ESMO) Congress - Madrid, Spain

Sep 8, 2017
12:00 AM

Additional Information

Title:   RX-3117, An Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Advanced Urothelial Cancer  [View Poster]

Title:  Phase 1 study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68,which prevents β-catenin Translocation in Advanced Solid Tumors  [View Poster]

Title:  A Novel Small Molecule Nucleoside Analog, RX-3117, Shows Potent Therapeutic Activity in Combination with Nab-paclitaxel and Checkpoint Inhibitors in Xenograft Models  [View Poster]

 

Remind Me



©2017 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy